Evaluating and Reporting Dysphagia in Trials of Chemoirradiation for Head-and-Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 727-733

  Gluck, Iris ^a   Feng, Felix Y ^a   Lyden, Teresa ^a   Haxer, Marc ^a   Worden, Francis ^b   Chepeha, Douglas B ^a   Eisbruch, Avraham ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chemoirradiation; CTCAE v3; Dysphagia; Head and neck cancer; Quality of life; Swallowing

Indexed keywords

ADVERSE EVENTS; COMMON TERMINOLOGY CRITERIA; FOUR-GROUP; HEAD-AND-NECK CANCER; OBSERVATION PERIOD; QUALITY OF LIFE;

TOXICITY; VIDEO RECORDING;

BIOLOGICAL ORGANS;

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DYSPHAGIA; FEMALE; FLUOROSCOPY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CANCER; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEGLUTITION; DEGLUTITION DISORDERS; FEMALE; FLUOROSCOPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 77952564597     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.049     Document Type: Article

References (52)

1. Ioannidis J.P., and Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285 (2001) 437-443
2. Scharf O., and Colevas A.D. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24 (2006) 3933-3938
3. Anderson S.J. Some thoughts on the reporting of adverse events in phase II cancer clinical trials. J Clin Oncol 24 (2006) 3821-3822
4. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
5. Cmelak A.J., Li S., Goldwasser M.A., et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25 (2007) 3971-3977
6. Cohen E.E., Haraf D.J., List M.A., et al. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol 24 (2006) 3438-3444
7. Garden A.S., Harris J., Vokes E.E., et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22 (2004) 2856-2864
8. Haraf D.J., Rosen F.R., Stenson K., et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9 (2003) 5936-5943
9. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in carcinoma of the head and neck. J Clin Oncol 18 (2000) 1458-1464
10. Kies M.S., Haraf D.J., Rosen F., et al. Concomitant paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19 (2001) 1961-1969
11. Machtay M., Rosenthal D.I., Hershock D., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma. J Clin Oncol 20 (2002) 3964-3971
12. Psyrri A., Kwong M., DiStasio S., et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation in head and neck cancer. J Clin Oncol 22 (2004) 3061-3069
13. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer. J Clin Oncol 23 (2005) 79-87
14. Sunwoo J.B., Herscher L.L., Kroog G.S., et al. Concurrent paclitaxel and radiation in head and neck cancer. J Clin Oncol 19 (2001) 800-811
15. Tsao A.S., Garden A.S., Kies M.S., et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for head and neck cancer. J Clin Oncol 24 (2006) 4163-4169
16. Vokes E.E., Kies M.S., Haraf D.J., et al. Concomitant chemoradiotherapy as primary therapy for advanced head and neck cancer. J Clin Oncol 18 (2000) 1652-1661
17. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy for head and neck cancer. J Clin Oncol 21 (2003) 320-326
18. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with head and neck cancer. J Clin Oncol 21 (2003) 92-98
19. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
20. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
21. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer. J Clin Oncol 24 (2006) 2873-2878
22. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 1125-1135
23. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
24. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
25. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
26. Fu K.K., Pajak T.F., Trotti A., et al. A RTOG phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck carcinomas. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
27. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22 (2004) 4665-4673
28. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7. Lancet 362 (2003) 933-940
29. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
30. Eisbruch A. Dysphagia and aspiration following chemo-irradiation of head and neck cancer: major obstacles to intensification of therapy. Ann Oncol 15 (2004) 363-364
31. Salama J.K., Seiwert T.Y., and Vokes E.E. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 25 (2007) 4118-4126
32. Rosenthal D.I., Lewin J.S., and Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24 (2006) 2636-2643
33. Langendijk J.A., Doornaert P., Verdonck-de Leeuw I.M., et al. Impact of late treatment-related toxicity on quality of life. J Clin Oncol 26 (2008) 3770-3776
34. Feng F.Y.F.Y., Kim H.M.H.M., Lyden T.H.T.H., et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68 (2007) 1289-1298
35. Eisbruch A., Lyden T., Bradford C.R., et al. Objective assessment of swallowing dysfunction and aspiration after chemoradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (2002) 23-28
36. Karnell M.P., and MacCracken E. A database information storage and reporting system for videofluorographic oropharyngeal swallowing evaluation. Am J Speech Language Pathol 8 (1994) 54-60
37. O'Neil K.H., Purdy M., Falk J., et al. The Dysphagia Outcome and Severity Scale. Dysphagia 14 (1999) 139-145
38. Terrell J.E., Nanavati K.A., Esclamado R.M., et al. Head and neck cancer-specific quality of life: Instrument validation. Arch Otolaryngol Head Neck Surg 123 (1997) 1125-1132
39. Hassan S.J., and Weymuller E.A. Jr. Assessment of quality of life in head and neck cancer. Head Neck 15 (1993) 485-496
40. Trotti A., Colevas A.D., Setser A., et al. CTCAE: development of a comprehensive grading system. Semin Radiat Oncol 13 (2003) 176-181
41. Trotti A., Pajak T.F., Gwede C.K., et al. TAME: Development of a new method for summarising adverse events of cancer treatment by RTOG. Lancet Oncol 8 (2007) 613-624
42. Hollen P.P.J., Gralla R.R.J., Cox C.C., et al. A dilemma in analysis: Issues in the serial measurement of quality of life. Lung Cancer 18 (1997) 119-136
43. Scott C. Statistical issues in studies of toxicity modifiers. Semin Radiat Oncol 12 (2002) 91-96
44. Wiklund I. Assessment of patient-reported outcomes in clinical trials. Fundamental Clin Pharmacol 18 (2004) 351-363
45. Mahoney M.R., Sargent D.J., O'Connell M.J., et al. Dealing with a deluge of data: an assessment of adverse event data. J Clin Oncol 23 (2005) 9275-9281
46. Bentzen S.M., and Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25 (2007) 4096-4103
47. Basch E., Iasonos A., McDonough T., et al. Patient versus clinician symptom reporting. Lancet Oncol 7 (2006) 903-909
48. Jensen K., Bonde Jensen A., and Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. Radiother Oncol 78 (2006) 298-305
49. Pauloski B.R., Rademaker A.W., Logemann J.A., et al. Swallow function and perception of dysphagia in patients with head and neck cancer. Head Neck 24 (2002) 555-565
50. Meirovitz A., Murdoch-Kinch C.A., Schipper M., et al. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of HN cancer. Int J Radiat Oncol Biol Phys 66 (2006) 445-453
51. Curran D., Giralt J., Harari P.M., et al. Quality of life in head and neck cancer patients after treatment with radiotherapy alone or with cetuximab. J Clin Oncol 25 (2007) 2191-2197
52. Trotti A., Colevas A.D., Setser A., et al. Patient-reported outcomes and evolution of adverse reporting in oncology. J Clin Oncol 25 (2007) 5121-5127